FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment

Stock News

04/14

FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX05-N, a recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection, intended for the treatment of metastatic colorectal cancer. Henlius plans to initiate related clinical studies for this drug once conditions are met. HLX05-N is a biosimilar of cetuximab injection independently developed by the group and is intended for treating metastatic colorectal cancer and head and neck squamous cell carcinoma. As of March 2026, the group's cumulative R&D investment in HLX05-N amounts to approximately RMB 54 million (unaudited). According to the latest data from IQVIA MIDAS, global sales of cetuximab injection reached about USD 1.658 billion in 2025.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1125283237"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125283237\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125283237?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125283237","market":"sg","top_or_hot":-1,"title":"FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment","media":"Stock News","content":"<p>FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX05-N, a recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection, intended for the treatment of metastatic colorectal cancer. Henlius plans to initiate related clinical studies for this drug once conditions are met. HLX05-N is a biosimilar of cetuximab injection independently developed by the group and is intended for treating metastatic colorectal cancer and head and neck squamous cell carcinoma. As of March 2026, the group's cumulative R&D investment in HLX05-N amounts to approximately RMB 54 million (unaudited). According to the latest data from IQVIA MIDAS, global sales of cetuximab injection reached about USD 1.658 billion in 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-04-14 17:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX05-N, a recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection, intended for the treatment of metastatic colorectal cancer. Henlius plans to initiate related clinical studies for this drug once conditions are met. HLX05-N is a biosimilar of cetuximab injection independently developed by the group and is intended for treating metastatic colorectal cancer and head and neck squamous cell carcinoma. As of March 2026, the group's cumulative R&D investment in HLX05-N amounts to approximately RMB 54 million (unaudited). According to the latest data from IQVIA MIDAS, global sales of cetuximab injection reached about USD 1.658 billion in 2025.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"醫美概念股","start_time":0,"source_url":"","article_id":"1125283237","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125283237","pubTimestamp":1776157835,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","BK0239":"医药制造","BK0183":"MSCI概念","BK0196":"行业龙头","BK0060":"抗癌","BK0175":"白马股","BK0012":"证金概念","BK0187":"一线龙头","BK0028":"国家队","BK1515":"抗疫概念","BK0096":"民营医院","02196":"复星医药","BK1191":"制药","BK0188":"融资融券"},"translate_title":"复星医药子公司HLX05-N癌症治疗I期试验获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX05-N, a recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection, intended for the treatment of metastatic colorectal cancer. Henlius plans to initiate related clinical studies for this drug once conditions are met. HLX05-N is a biosimilar of cetuximab injection independently developed by the group and is intended for treating metastatic colorectal cancer and head and neck squamous cell carcinoma. As of March 2026, the group's cumulative R&D investment in HLX05-N amounts to approximately RMB 54 million (unaudited). According to the latest data from IQVIA MIDAS, global sales of cetuximab injection reached about USD 1.658 billion in 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}